Dr. Whitworth on the Importance of Additional HER2 Subtyping

Pat Whitworth, MD
Published: Thursday, Dec 10, 2015



Pat Whitworth, MD, medical oncologist, Nashville Breast Center, discusses the prospective neoadjuvant NBRST study, which looked at BluePrint functional subtyping versus conventional immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) in breast tumors.

The BluePrint 80-gene functional molecular subtype assay is based on mRNA expression associated with intact translation to protein.

The study found that half of the tumors that would normally be identified as HER2-positive by FISH and estrogen receptor (ER)-positive by IHC were classified as luminal A subtype by BluePrint functional subtyping.

This group of patients, when treated with chemotherapy and traztumab, had a very low complete response (CR) rate, says Whitworth. However, when pertuzumab was added, the CR rate jumped dramatically, he says.

<<< View more from the 2015 San Antonio Breast Cancer Symposium



Pat Whitworth, MD, medical oncologist, Nashville Breast Center, discusses the prospective neoadjuvant NBRST study, which looked at BluePrint functional subtyping versus conventional immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) in breast tumors.

The BluePrint 80-gene functional molecular subtype assay is based on mRNA expression associated with intact translation to protein.

The study found that half of the tumors that would normally be identified as HER2-positive by FISH and estrogen receptor (ER)-positive by IHC were classified as luminal A subtype by BluePrint functional subtyping.

This group of patients, when treated with chemotherapy and traztumab, had a very low complete response (CR) rate, says Whitworth. However, when pertuzumab was added, the CR rate jumped dramatically, he says.

<<< View more from the 2015 San Antonio Breast Cancer Symposium


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize CareAug 29, 20181.5
Publication Bottom Border
Border Publication
x